• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Immunic Therapeutics

Monday, June 03, 2024
CP
CNS/Neurological
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. IMU-856 is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Immunic Therapeutics
Company Website: http://www.imux.com
Lead Product in Development: Vidofludimus Calcium (IMU-838)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Exchange

Nasdaq Stock Exchange

Ticker

IMUX

Website

http://www.imux.com

Company HQ City

New York City

Company HQ State

NY

Company HQ Country

United States

CEO/Top Company Official

Daniel Vitt, PhD

Lead Product in Development

Vidofludimus Calcium (IMU-838)

Development Phase of Primary Product

Phase III
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS